Findings published in the New England Journal of Medicine add support and new insight to the high level of protection
Continue reading »Home »
Birx warns coronavirus closures won't suffice in this phase of pandemic, report says
Fox News Flash top headlines for October 23 Fox News Flash top headlines are here. Check out what’s clicking on
Continue reading »Sanofi and GSK Initiate Phase 1/2 Clinical Trial of COVID-19 Adjuvanted Recombinant Protein-Based Vaccine Candidate
London, UK and Paris, France 03 September 2020 — Sanofi and GSK announce today the start of the Phase 1/2
Continue reading »South Africa begins second phase of reopening of schools
Thousands of South African students are returning to school Monday after nearly four months when their classes were closed to
Continue reading »EPA to phase out chemical testing on mammals
The eventual elimination of chemical testing on mammals was announced Tuesday by the U.S. Environmental Protection Agency. The agency plans
Continue reading »Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
DUBLIN, Jan. 28, 2019 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of
Continue reading »Results ‘encouraging’ from phase II trial for relapsed acute myeloid leukemia
There is a significant need for new treatments for patients with relapsed acute myeloid leukemia, a rare cancer of the
Continue reading »Argenx Doses First Patient in Global Phase 3 Registration Trial of Efgartigimod
September 06, 2018 — Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company
Continue reading »Breast Cancer Drug Promising in Phase 3 Trial
WEDNESDAY, Aug. 15, 2018 — For women with advanced breast cancer who carry the BRCA1 and BRCA2 gene mutations, an
Continue reading »Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved Gut Microbiome of Patients with CDI
Oxford, UK, and Cambridge, MA, US, 3 August 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the publication
Continue reading »